Abstract：Objective: To observe the quality of life and clinical efficacy on anlotinib hydrochloride in the treatment of advanced non-small cell lung cancer patients. Methods: 37 cases who were diagnosed with non-small cell lung cancer were collected from our hospital;anlotinib hydrochloride was administered to all patients, once a day, 12 mg a time, before breakfast, then the clinical efficacy, effect on patients' quality of life, and adverse reactions of anlotinib hydrochloride in the treatment of this disease were analyzed. Results: The objective remission rate was 35.1%, while the disease control rate of anlotinib hydrochloride was 89.2%. After treatment, the scores of daily life, emotional control, activity, social/family life and other scores of patients were higher than before treatment, and the total score (181.39±14.73) after treatment was higher than before treatment (160.73±12.16). The differences were statistically significant (P<0.05). Anlotinib hydrochloride had the highest incidence of hypertension in patients with non-small cell lung cancer after treatment, accounting for 13.5%, followed by hand-foot syndrome and thyroid dysfunction, accounting for 10.8% and 8.1%, respectively. Six of the patients had serious adverse reactions, accounting for 8.1%. Conclusion: Anlotinib has certain advantages in the efficacy and safety of treatment of non-small cell lung cancer, and can improve the quality of life of patients, and it can provide treatment for patients with second-and third-line chemotherapy failure and the refractory.
张玉, 李艳芳, 张改琴, 张有为. 盐酸安罗替尼治疗晚期非小细胞肺癌患者的临床疗效[J]. 河北医学, 2020, 26(10): 1742-1746.
ZHANG Yu, LI Yanfang, ZHANG Gaiqin, et al. The Clinical Efficacy of Anlotinib Hydrochloride in the Treatment of Advanced Non-Small Cell Lung Cancer Patients. HeBei Med, 2020, 26(10): 1742-1746.
2020, Vol. 26 
冀公网安备13080202000677号